Featuring: Dr. Sonia Quintas, MD, MSc, Theresa Veira, MSN, MBA, and Pora Kuperman, MPH, PhD
Migraine is a leading cause of disability in children and adolescents with prevalence of roughly 3% in younger children, yet the clinical picture often diverges from adults strengthening the need for a specialized approach.
Migraine in Pediatric Clinical Development
Attacks in children and adolescents are frequently shorter, more bilateral, and dominated by gastrointestinal symptoms, motion sensitivity, and vertigo. Younger patients may struggle to describe their pain or associated features, which directly impacts how these integral components are captured in a trial setting.
For most indications, pediatric clinical research is unique in both its approach and execution. Specifically, for migraine clinical trials, researchers must explicitly account for age-specific biology, symptom expression, and reporting ability while still satisfying regulatory expectations for robust data collection. Successful programs adapt to adult evidence, but do not simply extrapolate it, using pediatric‑specific eligibility criteria, endpoints, and training so that treatment effects are not obscured by noise.
Sponsors developing pediatric migraine preventives or acute therapies face a convergence of challenges such as:
- High Placebo Response
- Comprehensive Framework for IHS guidelines
Managing High Placebo Response in Pediatric Migraine Studies
In pediatric prevention studies, placebo response rates are often high. Medpace addresses this challenge with a multi-layered approach to placebo management. Standardized participant and rater education emphasize accurate and neutral reporting rather than “feeling better.” Language aligned with placebo-control reminder scripts is introduced at informed consent and reinforced at each visit. Our training is delivered consistently across sites to minimize variability in how expectations are framed. We also use structured pain-rating training, so participants learn to distinguish meaningful changes in intensity and frequency from random fluctuation.
Age-appropriate endpoints, PROMs, and caregiver input endpoints that work well in adults do not always capture what matters most for children and adolescents. School absenteeism, missed activities, and emotional distress often represent the true burden, and endpoint strategies must reflect this reality.
Evidence suggests that children over eight years old can reliably complete patient-reported outcome measures (PROMs) when instruments match their vocabulary and reading level. At the same time, studies consistently show only modest agreement between child self-report and parent proxy ratings, with parents frequently underestimating pain-related functional disability. Relying solely on proxy data can therefore underestimate benefit or misclassify responders.
Medpace’s expertise and experience working with this unique patient population allows us to integrate both perspectives. For younger children, we recommend validated pictorial scales such as the Faces Pain Scale, combined with simple numerical ratings for caregivers. For older children and adolescents, migraine-specific disability tools like PedMIDAS, quality-of-life instruments, and mood/anxiety scales are selected and adapted according to IHS guidance and regulatory expectations. Protocols are written to include both patient and proxy PROMs as complementary, not interchangeable, sources of information.
Operationalizing IHS Pediatric Migraine Trial Guidelines
The IHS guidelines for preventive migraine trials in children and adolescents provide a comprehensive framework, from eligibility definitions to baseline duration, treatment length, and outcome hierarchies.
Key design elements include clearly defined age strata (6-11 and 12-17 years), use of the latest International Classification of Headache Disorders criteria tailored to pediatric features, a minimum 28‑day prospective baseline (often up to 56 days when frequency is unstable), and at least 12 weeks of randomized treatment.
Effective trials should also address comorbidities (such as anxiety, depression, obesity, and chronic pain), medication-overuse headaches, and concomitant preventive therapies. Medpace’s pediatric neurologists and statisticians work with Sponsors to translate these guidelines into practical, globally executable protocols.
For Sponsors seeking a more comprehensive view of migraine trial design and therapeutic development our full whitepaper provides additional insights.
Why Sponsors Choose Medpace for Pediatric Migraine Programs
At Medpace, pediatric migraine trials benefit from embedded, highly experienced neurologists with specific expertise in pediatric pain and headache disorders. These physicians are involved in early feasibility and protocol design through site selection, investigator training, and ongoing medical monitoring. They can engage directly with regulatory agencies when scientific or ethical questions arise around inclusion criteria, placebo use, or endpoint strategy.
Operationally, Medpace’s full-service model—spanning site start-up, global project management, data management, biostatistics, medical writing, and pharmacovigilance—ensures that complex pediatric requirements are coordinated rather than fragmented across vendors. By combining deep therapeutic expertise with disciplined execution, Medpace helps accelerate the development of effective, safe therapies that meaningfully improve the lives of children and adolescents living with migraine.